Skip to main content
CAMP logo

CAMP · Camp4 Therapeutics Corp

Track CAMP — free
$3.96 +0.10 (+2.46%)
Market Cap
$242.23M
Shares
62.75M
Volume · Nov 17 130.23K Avg daily vol (3M) 246.59K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.86 Open$3.83 Day$3.58–4.08 52W close$2.90–7.13 Avg vol 30d173K Short int3.3M · 5.2% of shares · 23.7d Short vol77% Last earningsNov 21, 2024 DataOct 2024–Nov 2026 Filing10-Q · Nov 5

Up next

call held Nov 21, 2024

Latest documents

2026
Nov 9
Investor event
SYNGAP1 dosing is CAMP4’s next key milestone

CAMP4 expects to dose first patients in a Phase 1-2 SYNGAP1 study by the end of the year, with data in the first half of 28. It ended Q3 with $124,500,000, providing runway through 2028 to advance Shank 3.

7 source passages
So CAMP4 is using antisense oligonucleotides to increase gene expression. you expect the first patients to be dosed by the end of the year. We're going directly into patients. It's a phase 1-2. the cake will be baked and ready to be eaten in the first half of 28 We have $124,500,000, $124 million, let's call it, at the end of Q3. It takes us to the end of 2028. We can also advance our Shank 3 program as well as the other Undisclosed programs as well. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ASCEND trial first patient expected in fourth quarter of 2026

The ASCEND Phase 1/2 clinical trial is expected to dose its first patient in the fourth quarter of 2026. Cash and cash equivalents were $124.5 million on September 30, 2026, expected to fund operations through the end of 2028.

Revenue $1.9M ▲ 138.9% Net loss $28.96M Diluted EPS -$0.37
Read from the MD&A section
2 source passages
We expect to dose the first patient in the ASCEND Phase 1/2 clinical trial in the fourth quarter of 2026. As of September 30, 2026, we had cash and cash equivalents of $124.5 million. Based on our current operating plan, we estimate that our cash and cash equivalents as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements through the end of 2028. Open the document at this passage
Nov 5
Current report 8-K
CMP-002 trial launches with $124.5 million cash

CAMP4 Therapeutics launched the ASCEND Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. It reported $124.5 million in cash and a $29.0 million quarterly net loss.

4 source passages
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate highlights. The Company has initiated the ASCEND Phase 1/2 clinical trial of CMP-002 and remains on track to dose the first patient by year-end 2026. Cash and cash equivalents as of September 30, 2026 were $124.5 million, compared to $109.5 million as of December 31, 2025. Net loss for the quarter ended September 30, 2026 was $29.0 million, compared to $15.1 million for the quarter ended September 30, 2025. Open the document at this passage
Sep 28
Current report 8-K
Regulation FD disclosure, Other events

CAMP4 THERAPEUTICS CORPORATION expects to dose the first patient in its ASCEND trial of CMP-002 by the end of 2026 and targets topline data in the first half of 2028. It also expects a SHANK3 development candidate in 2027.

Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.78M ▲ 18.8% Net loss $33.53M Diluted EPS -$0.58
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.32M
Trailing 12 months
Net income (TTM)
−$121.10M
Trailing 12 months
Revenue growth YoY
+138.9%
Year over year
Operating margin
-1,001.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$124.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+189.4%
Year over year · more shares
Price change (1Y)
-5.9%
Trailing year
Short interest
5.2%
Latest settlement · 23.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +0%
above
RSI (14) 50
neutral
MACD trend Positive
52-week position 23%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +23%
trailing
6-month return −8%
trailing
YTD return −37%
this year
Relative strength −7%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +13 funds added
Insider flow Distributing
Net -$2.5M over 90 days · 67% sells
Short interest Falling
5.19% of shares out · ▼ -5.6% MoM · 23.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
67 holders — near 2-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Strong
Revenue growth +437%
Y/Y
EPS growth +76%
Y/Y
Free cash flow $-29.8M
Balance sheet $109.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 110%
annualized · 1-yr
Max drawdown −58%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Sep 30, 2020
Cash basis tax rate · remainder of this fiscal year 3.5% – 5.5%
Previous outlook earlier release · from the Earnings Call filed Jun 30, 2020

Still-open targets the latest release did not restate under the same label.

Gross margin · exit the year 41% – 42%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+0% Bullish
RSI (14)
50 Neutral
MACD trend
Positive Bullish
52-week position
23% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +13 funds added
Insider flow Distributing
Net -$2.5M over 90 days · 67% sells
Short interest Falling
5.19% of shares out · ▼ -5.6% MoM · 23.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
67 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 23% Range high $7
vs 200-day avg -8% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CAMP
Camp4 Therapeutics Corp
this stock
$242.23M -37.0% +436.5% — 5.2%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$83.08B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
67
% held
82.6%
Net QoQ
+10.1M sh
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
73
View
Short & Settlement
Short Interest Falling
Shares short
3.3M
Days to cover
23.7d
Change
-191.8K sh
View
Short Volume
Short vol %
77%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$6.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
30.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.5M
Buyers / Sellers
1 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$3.5M
Net income (FY)
$-80.4M
EPS diluted
$-2.65
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 9, 2026
This year
23

CAMP4 expects to dose first patients in a Phase 1-2 SYNGAP1 study by the end of the year, with data in the first half of 28. It ended Q3 with $124,500,000, providing runway through 2028 to advance Shank 3.

View
Exempt Offerings
Offering
Indefinite
Filed
Jun 21, 2022
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
CAMP4 Reports Second Quarter 2026…
Published
Aug 13, 2026
View

Performance

5D 20D 120D MTD YTD
CAMP -17.7% +22.9% -8.3% -2.5% -37.0%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -16.0% +26.4% -6.9% -0.4% -45.5%
Key facts CIK 1736730 CUSIP 13463J101 13F (30d) 69 filings 66 filers Visit website Investor relations